News
Last year, Bristol Myers Squibb also returned rights to AGEN1777, a TIGITxCD96 bispecific antibody partnered with Agenus in a $1.56 billion deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback